Mutation May Be Associated With Resistance to NSCLC Immunotherapy – AJMC.com Managed Markets Network
|
Mutation May Be Associated With Resistance to NSCLC Immunotherapy
AJMC.com Managed Markets Network Researchers led by cancer biologist Katerina Politi, PhD, associate professor in the Yale Department of Pathology and Medical Oncology, have discovered that a mutation in a viral protein called B2M prevents the immune activation needed for … |
